We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Stoke Therapeutics
STOK
$1.99B
| $1.16M | 0.01% |
94,382
-5,800
| -6% | -$82.2K |
|
502
Hanover Insurance
THG
$7.98B
| $1.15M | 0.01% |
+7,750
| New | +$1.06M |
|
503
Tenable Holdings
TENB
$3.97B
| $1.14M | 0.01% |
+28,249
| New | +$1.18M |
|
|
IGMS
504
DELISTED
IGM Biosciences
IGMS
| $1.11M | 0.01% |
67,259
-7,741
| -10% | -$84.8K |
|
|
BBOT
505
BridgeBio Oncology
BBOT
$718M
| $1.08M | 0.01% |
103,247
| – | – |
|
506
Appian
APPN
$2.2B
| $1.07M | 0.01% |
31,373
+6,308
| +25% | +$204K |
|
507
Fractyl Health
GUTS
$109M
| $1.06M | 0.01% |
419,975
+160,427
| +62% | +$523K |
|
508
Penumbra
PEN
$12.7B
| $992K | 0.01% |
+5,105
| New | +$965K |
|
|
RVPH
509
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $986K | 0.01% |
34,240
-45,399
| -57% | -$1.01M |
|
510
Alkami Technology
ALKT
$2.01B
| $966K | 0.01% |
30,623
+19,345
| +172% | +$611K |
|
|
ABVX
511
Abivax
ABVX
$10.9B
| $942K | 0.01% |
81,730
+50,446
| +161% | +$604K |
|
512
JFrog
FROG
$10.2B
| $901K | 0.01% |
31,039
+11,170
| +56% | +$351K |
|
513
Apple
AAPL
$4.54T
| $884K | 0.01% |
3,792
-29
| -0.8% | -$6.48K |
|
|
BOW
514
Bowhead Specialty Holdings
BOW
$1.1B
| $868K | 0.01% |
31,000
-31,000
| -50% | -$869K |
|
515
Kiniksa Pharmaceuticals
KNSA
$6.09B
| $850K | 0.01% |
+34,029
| New | +$829K |
|
516
Amplitude
AMPL
$1.33B
| $845K | 0.01% |
94,223
-419
| -0.4% | -$3.57K |
|
517
Manhattan Associates
MANH
$11.2B
| $830K | 0.01% |
2,949
-64,048
| -96% | -$16.3M |
|
|
MRSN
518
DELISTED
Mersana Therapeutics
MRSN
| $819K | 0.01% |
17,342
-41,350
| -70% | -$1.82M |
|
519
Outlook Therapeutics
OTLK
$193M
| $809K | 0.01% |
151,508
+722
| +0.5% | +$5.28K |
|
520
Microsoft
MSFT
$3.62T
| $806K | 0.01% |
1,872
-130,829
| -99% | -$55.9M |
|
521
Aligos Therapeutics
ALGS
$29.3M
| $796K | 0.01% |
91,971
+70,723
| +333% | +$880K |
|
522
Peabody Energy
BTU
$2.78B
| $791K | 0.01% |
+29,797
| New | +$679K |
|
523
Gossamer Bio
GOSS
$86.9M
| $777K | 0.01% |
787,288
+5,510
| +0.7% | +$5.3K |
|
524
Regal Rexnord
RRX
$12.2B
| $767K | 0.01% |
4,623
-46,777
| -91% | -$7.23M |
|
|
DOCU
525
DocuSign
DOCU
$11B
| $719K | 0.01% |
+11,584
| New | +$649K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.